a new molecule for the treatment of schizophrenia is currently being developed and is currently in phase 1 development. this is a new molecule that is designed to leverage the learnings from pimavanserin and hit the nice sweet spot. this is a new molecule designed to leverage the learnings from pimamvanserin and hit the nice sweet spot and will continue to support the dissemination of these important sets within the treating community.